Protocols
ABBVIE-M22-947 Phase I OPEN TO ACCRUAL
A Dose Escalation and Expansion Study of AbbVie's Compound in Combination with Anti-Cancer Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
ASTELLAS-2215-CL-0203 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, Multicenter, Open-label, Single Arm, Dose Escalation and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy
BEIGENE-BGB-11417-103 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies
BEIGENE-BGB-11417-105 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination with Dexamethasone and Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and t(11;14)
CARNABIOSCIENCES-C1763102 Phase I OPEN TO ACCRUAL
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non Hodgkin Lymphoma
CHIMAGEN-CMG1A46-US01 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, First in Human, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Triple-Specific T-Cell Engager 1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-Cell Hematologic Malignancies
COLUMBIAUNIVERSITY-AAAT8639 Phase I/II OPEN TO ACCRUAL
An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis
DISC-0974-102 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2a Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
HOFFMANNLAROCHE-GO43693 Phase I OPEN TO ACCRUAL
A Phase Ib, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients with Relapsed/Refractory Transplant Eligible Diffuse B-Cell Lymphoma
ICHNOS-ISB-1442-101 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
IIT-ATALLAH-MCW-XEN21 Phase I OPEN TO ACCRUAL
MCW-XEN21: A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients with Relapsed/Refractory CD38 Positive Acute Leukemia and T Cell Lymphoblastic Lymphoma
IIT-HAMADANI-ADCT-LONCA Phase I OPEN TO ACCRUAL
A Multicenter Phase 1, Open-Label Trial of Loncastuximab Tesirine in Combination with DA-EPOCH-R in Patients with Previously Untreated Aggressive B-cell Lymphoid Malignancies
JNJ-75276617ALE1001 Phase I OPEN TO ACCRUAL
A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia
KGA-ZN-D5-004C Phase I/II OPEN TO ACCRUAL
A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the WEE1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia
MEI-ME-522-001 Phase I OPEN TO ACCRUAL
A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and/or Refractory Acute Myeloid Leukemia
NURIX-NX-5948-301 Phase I OPEN TO ACCRUAL
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
ORYZON-CL04-ORY-1001 Phase I OPEN TO ACCRUAL *
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like Tyrosine Kinase Mutation (FLT3 Mut+): The FRIDA Study
SCHRODINGER-SGR-1505-101 Phase I OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Patients with Mature B-Cell Malignancies
TENEOBIO-TENEOTWO-TNB486-001 Phase I OPEN TO ACCRUAL
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
UAB-19113-NTX-301 Phase I OPEN TO ACCRUAL
A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients with MDS and AML